Monitoring analysis of the use of biosimilar medicines in the Campania region (southern Italy) to support effective and sustainable care.

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL

Wiener medizinische Wochenschrift Pub Date : 2025-03-05 DOI:10.1007/s10354-025-01071-1

Francesco Ferrara, Andrea Zovi, Roberto Langella, Maurizio Capuozzo

{"title":"Monitoring analysis of the use of biosimilar medicines in the Campania region (southern Italy) to support effective and sustainable care.","authors":"Francesco Ferrara, Andrea Zovi, Roberto Langella, Maurizio Capuozzo","doi":"10.1007/s10354-025-01071-1","DOIUrl":null,"url":null,"abstract":"Background: Biosimilar drugs offer a valuable opportunity for healthcare systems worldwide, providing significant cost savings and ensuring the same level of effectiveness and safety in the treatment of chronic conditions. These savings can be reinvested into continuous medical innovations.Methods: A search was carried out to assess the use of key biosimilar medications across various therapeutic areas within an Italian health authority that serves a population of over 1 million people. Data on usage, costs, and the number of patients treated were obtained from the company databases. In addition, a comparison with the year 2022 was performed, aiming to identify any increase in the use of biosimilar drugs during 2023.Results: The analysis of 2023 revealed that a large majority of the studied active ingredients are administered as biosimilar medications, with only a few exceptions. Resistance remains in the prescription of adalimumab and etanercept, with spending on the originators of close to 3 million euros.Conclusion: The comparison between 2023 and 2022 highlighted the growing adoption of biosimilar medications. This positive trend suggests the potential for achieving full utilization in the near future. Such a result would significantly benefit the national healthcare system and the public, ensuring a healthcare approach that is both effective and sustainable.","PeriodicalId":23882,"journal":{"name":"Wiener medizinische Wochenschrift","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiener medizinische Wochenschrift","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s10354-025-01071-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biosimilar drugs offer a valuable opportunity for healthcare systems worldwide, providing significant cost savings and ensuring the same level of effectiveness and safety in the treatment of chronic conditions. These savings can be reinvested into continuous medical innovations.

Methods: A search was carried out to assess the use of key biosimilar medications across various therapeutic areas within an Italian health authority that serves a population of over 1 million people. Data on usage, costs, and the number of patients treated were obtained from the company databases. In addition, a comparison with the year 2022 was performed, aiming to identify any increase in the use of biosimilar drugs during 2023.

Results: The analysis of 2023 revealed that a large majority of the studied active ingredients are administered as biosimilar medications, with only a few exceptions. Resistance remains in the prescription of adalimumab and etanercept, with spending on the originators of close to 3 million euros.

Conclusion: The comparison between 2023 and 2022 highlighted the growing adoption of biosimilar medications. This positive trend suggests the potential for achieving full utilization in the near future. Such a result would significantly benefit the national healthcare system and the public, ensuring a healthcare approach that is both effective and sustainable.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiener medizinische Wochenschrift MEDICINE, GENERAL & INTERNAL-

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： ''From the microscope to clinical application!'', Scientists from all European countries make available their recent research results and practical experience through Wiener Medizinische Wochenschrift, the renowned English- and German-language forum. Both original articles and reviews on a broad spectrum of clinical and preclinical medicine are presented within the successful framework of thematic issues compiled by guest editors. Selected cutting-edge topics, such as dementia, geriatric oncology, Helicobacter pylori and phytomedicine make the journal a mandatory source of information.